Transient transcription factor (OSKM) expression is key towards clinical translation of in vivo cell reprogramming

Kostas Kostarelos, Irene de Lázaro, Giulio Cossu

Research output: Contribution to journalComment/debatepeer-review

Abstract

Reprogramming adult, fully differentiated cells to pluripotency in vivo via Oct3/4, Sox2, Klf4and c-Myc (OSKM) overexpression has proved feasible in various independent studies and could be used to induce tissue regeneration owing to the proliferative capacity and differentiation potential of the reprogrammed cells. However, a number of these reports have described the generation of teratomas caused by sustained reprogramming, which precludes the therapeutic translation of this technology. A recent study by the Izpisúa-Belmonte laboratory described a cyclic regime for short-term OSKM expression in vivothat prevents complete reprogramming to the pluripotent state as well as tumorigenesis. We comment here on this and other studies that provide evidence that in vivo OSKM induction can enhance tissue regeneration, while avoiding the feared formation of teratomas. These results could inspire more research to explore the potential of in vivoreprogramming in regenerative medicine.
Original languageEnglish
Pages (from-to)733-736
JournalEMBO Molecular Medicine
Volume9
Issue number6
DOIs
Publication statusPublished - 2017

Fingerprint

Dive into the research topics of 'Transient transcription factor (OSKM) expression is key towards clinical translation of in vivo cell reprogramming'. Together they form a unique fingerprint.

Cite this